NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02606461,Selinexor in Advanced Liposarcoma,https://clinicaltrials.gov/study/NCT02606461,SEAL,COMPLETED,"This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).",YES,Dedifferentiated Liposarcoma,DRUG: Selinexor|DRUG: Placebo,"Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, PFS was defined as the time from the date of randomization until the first date of Independent Review Committee (IRC)-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions., From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)|Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1, PFS was defined as the time from the date of randomization in the Phase 3 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)|Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1, PFS was defined as the time from date of randomization until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)|Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1, PFS was defined as the time from date of randomization in the Phase 2 open-label period until the first date of IRC-confirmed PD per RECIST version 1.1, or death due to any cause. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)","Phase 3 Double Blind: Overall Survival (OS), OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier., From date of randomization until death due to any cause, whichever occurred first (up to 70 months)|Phase 3 Open Label: Overall Survival (OS), OS was defined as the duration (in months) from the date of randomization in the Phase 3 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier., From date of randomization in phase 3 open label period until death due to any cause, whichever occurred first (up to 70 months)|Phase 2 Double Blind: Overall Survival (OS), OS was defined as the duration (in months) from the date of randomization to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier., From the date of randomization until death due to any cause, whichever occurred first (up to 70 months)|Phase 2 Open Label: Overall Survival (OS), OS was defined as the duration (in months) from the date of randomization in the Phase 2 open-label period to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier., From date of randomization in the Phase 2 open-label period until death due to any cause, whichever occurred first (up to 70 months)|Phase 3 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1, TTP was defined as the time from date of randomization until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)|Phase 3 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1, TTP was defined as the time from date of randomization in the Phase 3 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From date of randomization in the Phase 3 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)|Phase 2 Double Blind: Time-to-Progression (TTP) as Per RECIST Version 1.1, TTP was defined as the time from date of randomization until ICR-determined PD as per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)|Phase 2 Open Label: Time-to-Progression (TTP) as Per RECIST Version 1.1, TTP was defined as the time from date of randomization in the Phase 2 open-label period until ICR-determined PD per RECIST version 1.1, or death due to disease progression, whichever occurred first. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From date of randomization in the Phase 2 open-label period until the first date of PD or death due to any cause, whichever occurred first (up to 70 months)|Phase 3 Double Blind: Overall Response Rate (ORR), ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR), per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters., From date of randomization until the documentation of CR or PR (up to 70 months)|Phase 3 Open Label: Overall Response Rate (ORR), ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters., From date of randomization in the Phase 3 open label period until the documentation of CR or PR (up to 70 months)|Phase 2 Double Blind: Overall Response Rate (ORR), ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters., From date of randomization until the documentation of CR or PR (up to 70 months)|Phase 2 Open Label: Overall Response Rate (ORR), ORR was defined as the percentage of participants who achieved CR or PR, per RECIST v.1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters., From date of randomization in the Phase 2 open-label period until the documentation of CR or PR (up to 70 months)|Phase 3 Double Blind: Duration of Response (DOR), DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From first occurrence of CR or PR until the first date of PD (up to 70 months)|Phase 3 Double Blind: Progression-free Survival (PFS) as Per Investigator Assessment, PFS was defined as the time from date of randomization until the first date of PD, per RECIST version 1.1, or death due to any cause as defined by the Investigator based on clinical and/or radiologic criteria. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions., From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 70 months)|Phase 3 Double Blind: Time to Next Treatment (TTNT), TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first., Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)|Phase 2 Double Blind: Time to Next Treatment (TTNT), TTNT was defined as time since randomization until the first new antineoplastic therapy or death due to any cause, whichever occurs first., Time from randomization to the first new antineoplastic therapy or death due to any cause (up to 70 months)|Phase 3 Double Blind: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs, An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs., From start of study drug administration up to 70 months|Phase 3 Open Label: Number of Participants With TEAEs and Serious TEAEs, An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs., From start of study drug administration up to 70 months|Phase 2 Double Blind: Number of Participants With TEAEs and Serious TEAEs, An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs., From start of study drug administration up to 70 months|Phase 2 Open Label: Number of Participants With TEAEs and Serious TEAEs, An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs., From start of study drug administration up to 70 months|Phase 3 Double Blind: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30), The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status)., Baseline up to Day 1387|Phase 3 Open Label: Change From Baseline in Quality-of-life Questionnaire 30 Item (QLQ-C30), The QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of patients with cancer. QLQ-C30 contains 30 questions that include five functional scales (physical, role, emotional, social, and cognitive functioning); three symptom scales (fatigue, nausea/vomiting and pain); six single-item symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties); and global health status/quality of life (QoL). Most questions used a 4-point scale (from 1 'Not at all' to 4 'Very much'); 2 questions used a 7-point scale (from 1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to a 0-100 scale. For the functional scales and the global health status/QoL, a higher score represents a better level of functioning (better health status); for the symptom scales/items, a higher score represents a higher level of symptomatology/problems (worse health status)., Baseline up to Day 379",,Karyopharm Therapeutics Inc,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2|PHASE3,342,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",KCP-330-020|2015-003594-14,2016-01-04,2020-10-28,2021-10-26,2015-11-17,2021-12-07,2023-01-23,"Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|University of California, Los Angeles, Los Angeles, California, 90095, United States|Sarcoma Oncology Center, Santa Monica, California, 90403, United States|Stanford University, Stanford, California, 94305, United States|University of Colorado-Denver, Denver, Colorado, 80202, United States|Yale Cancer Center, New Haven, Connecticut, 06520-8032, United States|Mayo Clinic, Jacksonville, Florida, 32224, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|Johns Hopkins, Baltimore, Maryland, 21231, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|Mayo Clinic Rochester, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Columbia University Medical Center, New York, New York, 10032, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Northwell Health Physicians Partners, New York, New York, 11042, United States|Duke Institute of Cancer, Durham, North Carolina, 27710, United States|James Cancer Center, Ohio State University, Columbus, Ohio, 43210-1240, United States|Oregon Health and Science, Portland, Oregon, 97239, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19106, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt, Nashville, Tennessee, 37232, United States|MD Anderson, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|UZ Brussel, Brussels, 1090, Belgium|UCL Saint-Luc, Brussels, 1200, Belgium|UZ Gent, Ghent, 9000, Belgium|Cross Cancer Center - Alberta Health Services, Edmonton, Alberta, T6G1Z2, Canada|The Ottawa Hospital Cancer, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|McGill University, Montréal, Quebec, H4A3J1, Canada|Institut Bergonie, Bordeaux,, 33076, France|Oscar Lambret Center, Lille Cedex 307, 59020, France|Centre Leon Berard, Lyon Cedex, 96373, France|Timone University Hospital, Marseille Cedex 5, 13385, France|Institut Régional du Cancer de Montpellier (ICM), Montpellier, 34298, France|CLCC Antoine Lacassagne, Nice, 06789, France|Institut Curie, Paris, 75248, France|Institut Claudius Regaud, Toulouse, 31059, France|Institut Gustave Roussy, Villejuif, 94110, France|Helios Hospital Berlin-Buch, Berlin, 13125, Germany|Technische Universitaet Dresden Med. Fakultaet Carl Gustav Carus Med. Klinik u. Poliklinik I, Dresden, 01307, Germany|National Center for Tumor Diseases, Univeristy Hospital Heidelberg, Heidelberg, 69120, Germany|University Hospital Mannheim, Mannheim, 68167, Germany|Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie Klinikum rechts der Isar der TU Muenchen, Muenchen, 81675, Germany|Soroka University Medical Center, Be'er Sheva, 84101, Israel|Hadassah Medical Center, Jerusalem, 91120, Israel|Rabin Medical Center, Petach Tikva, 4941492, Israel|Sheba Medical Center, Ramat Gan, 52621, Israel|Tel Aviv Sourasky Medical, Tel Aviv, 64239, Israel|Assaf Harofe Medical Center, Zerifin, 7030000, Israel|Candiolo Cancer Institute, Candiolo, 10060, Italy|Istituto Nazionale dei Tumori, Milan, Milano, 20133, Italy|U.O.C. Oncologia Medica Oncology Department, Palermo, 90127, Italy|Policlinico Universitario Campus Biomedico, Roma, 00128, Italy|""Germans Trias Pujol"" University Hospital, Badalona, 41013, Spain|Vall d´hebron University Hospital, Barcelona, 08035, Spain|Hospital Sant Pau Barcelona, Barcelona, 08041, Spain|Hospital ICO Bellvitge, Barcelona, 08908, Spain|Hospital Universitario Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Hospital La Fe Valencia, Valencia, 46026, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, 413 45, Sweden|Skane University Hospital, Lund, 221 85, Sweden|Onkologiska Kliniken, Stockholm, 171 76, Sweden|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|University College London Hospitals, London, NW1 2BU, United Kingdom|The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom|The Christie, Manchester, M20 4BX, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/61/NCT02606461/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/61/NCT02606461/SAP_001.pdf"
